Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse-Reference-Cited by-同舟云学术

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse

Published:2024-03 Issue:3 Volume:5 Page:101471
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Chen Mengnuo,Mainardi Sara,Lieftink Cor,Velds Arno,de Rink Iris,Yang Chen,Kuiken Hendrik J.,Morris Ben,Edwards Finn,Jochems Fleur,van Tellingen Olaf,Boeije Manon,Proost Natalie,Jansen Robin A.,Qin Shifan,Jin Haojie,Koen van der Mijn J.C.,Schepers Arnout,Venkatesan Subramanian,Qin Wenxin,Beijersbergen Roderick L.,Wang Liqin,Bernards René^ORCID

Publisher

Elsevier BV

Reference34 articles.

1. Drug-Tolerant Persister Cells in Cancer Therapy Resistance;Dhanyamraju;Cancer Res.,2022

2. Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells;De Conti;Cancers,2021

3. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations;Sharma;Cell,2010

4. Cycling cancer persister cells arise from lineages with distinct programs;Oren;Nature,2021

5. H3K27me3 conditions chemotolerance in triple-negative breast cancer;Marsolier;Nat. Genet.,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the Use of Cell Lines in Studies of Selenium-Dependent Glutathione Peroxidase 2 (GPX2) Involvement in Colorectal Cancer;Diseases;2024-09-10

2. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

3. Two-polarized roles of transcription factor FOSB in lung cancer progression and prognosis: dependent on p53 status;Journal of Experimental & Clinical Cancer Research;2024-08-21

4. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies;Signal Transduction and Targeted Therapy;2024-08-14

5. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma;Cell Reports Medicine;2024-08